Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms

Gitte Dam*, Henning Grønbæk, Anna Sundlöv, Johan Botling, Anders Sundin, Rene Horsleben Petersen, Staffan Welin, Espen-Thiis Evensen, Halfdan Sorbye, Elizaveta Tabaksblat, Anne Kirstine Arveschoug, Jann Mortensen, Andreas Kjaer, Ulrich Knigge, Eva Tiensuu Janson, Seppo W Langer

*Corresponding author for this work
1 Citation (Scopus)


Lung neuroendocrine neoplasms (NEN) are a heterogeneous population of neoplasms with different pathology, clinical behavior, and prognosis compared to the more common lung cancers. The diagnostic work-up and treatment of patients with lung- NEN has undergone major recent advances and new methods are currently being introduced into the clinic. These Nordic guidelines summarize and update the Nordic Neuroendocrine Tumor Group's current view on how to diagnose and treat lung NEN-patients and are meant to be useful in the daily practice for clinicians handling these patients. This review reflects our view of the current state of the art of diagnosis and treatment of patients with lung-NEN. Small cell lung carcinoma (SCLC) is not included in these guidelines.

Original languageEnglish
JournalActa Oncologica
Issue number5
Pages (from-to)431-437
Number of pages7
Publication statusPublished - May 2023


  • Carcinoma, Neuroendocrine
  • Humans
  • Lung Neoplasms/diagnosis
  • Lung/pathology
  • Neuroendocrine Tumors/diagnosis
  • Pancreatic Neoplasms/pathology
  • Prognosis
  • treatment
  • Lung
  • bronchopulmonary neoplasm
  • neuroendocrine carcinoma
  • diagnosis
  • neuroendocrine neoplasm


Dive into the research topics of 'Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms'. Together they form a unique fingerprint.

Cite this